The B4GALT1 Knockout KYSE-150 Polyclonal Cells comprise a heterogeneous population of KYSE-150 human esophageal squamous cell carcinoma cells engineered via CRISPR/Cas9-mediated gene disruption to abolish B4GALT1 expression. This polyclonal knockout pool retains the genetic diversity arising from the editing process, providing a valuable loss-of-function model for studying the roles of B4GALT1 in glycosylation-dependent processes without isolation of individual clones.
Derived from a poorly differentiated human esophageal squamous cell carcinoma, the KYSE-150 cell line is widely employed in cancer research for investigating tumor cell proliferation, invasion, and drug sensitivity. Its molecular profile, including TP53 mutations, renders it a relevant in vitro system for esophageal cancer biology and for evaluating oncogenic signaling pathways and therapeutic vulnerabilities.
B4GALT1 encodes beta-1,4-galactosyltransferase 1, which catalyzes the transfer of galactose from UDP-galactose to N-acetylglucosamine residues on glycoproteins and glycolipids, generating Gal??1-4GlcNAc termini. These glycan structures act as ligands for galectins such as galectin-1 and galectin-3 and modulate the function of integrin receptors, focal adhesion kinase (FAK), SRC, and downstream ERK signaling. The B4GALT1 gene is transcriptionally regulated by SP1, CREB, and NF-??B in response to growth factors and cytokines, and the enzyme can interact with alpha-lactalbumin to form the lactose synthase complex. Knockout of B4GALT1 eliminates these specific glycosylation events, thereby disrupting galectin binding, integrin-mediated cell adhesion, and intracellular signaling cascades.
In the KYSE-150 esophageal cancer context, disruption of B4GALT1 abrogates the synthesis of Gal??1-4GlcNAc epitopes on cell surface glycoconjugates, impairing galectin-mediated lattice formation and integrin clustering. This loss is anticipated to reduce adhesion to extracellular matrix components, diminish migratory and invasive capacity, and alter pro-survival signaling via FAK/SRC/ERK pathways. Thus, these polyclonal knockout cells provide a physiologically appropriate model to dissect the contribution of specific glycan modifications to esophageal squamous cell carcinoma progression.
These polyclonal knockout cells are ideally suited for glycobiology and cancer research applications, including functional analyses of galectin-mediated signaling, characterization of altered glycosylation patterns via lectin blotting and flow cytometry, and quantitative assessments of cell adhesion, wound closure, and transwell migration/invasion. They facilitate the study of drug resistance mechanisms and transcriptomic profiling by RNA-seq to identify downstream targets and compensatory networks affected by B4GALT1 loss. For further technical information or custom cell engineering inquiries, please contact Ascent Research.
